Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec;44(12):4441-3.
doi: 10.1128/JCM.01312-06. Epub 2006 Oct 11.

Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients

Affiliations

Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients

Masahiro Onozawa et al. J Clin Microbiol. 2006 Dec.

Abstract

Reactivation of latent varicella-zoster virus (VZV), presenting as localized zoster or as disseminated infection, is a common and potentially serious complication in hematopoietic stem cell transplantation (HSCT) recipients. We retrospectively studied anti-VZV immunoglobulin G titers by the immune adherence hemagglutination method after HSCT and also studied VZV DNA by real-time PCR during clinical VZV reactivation using cryopreserved serum samples. No significant difference was found between anti-VZV titers in 13 patients with VZV infection (localized zoster in 11 patients and disseminated zoster in 2 patients) and in 13 subjects without VZV infection at each time point after HSCT. Preexisting anti-VZV titers of disseminated zoster cases tended to be lower than those of localized zoster cases (P=0.10). Serum VZV DNA copy numbers at the onset of disseminated zoster cases tended to be higher than those of localized zoster cases (P=0.09). A strong inverse correlation was found between preexisting anti-VZV titer and serum VZV DNA at onset (r=-0.90, P=0.006). In HSCT recipients, preexisting antibody does not prevent the development of VZV reactivation but may contribute to decreased viral load at onset, resulting in a mild clinical course.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Transition of anti-VZV titer after HSCT (control, ▴; localized zoster, •; disseminated zoster, ○). In cases of VZV infection, only the results before VZV onset were plotted. (B) Transition of anti-VZV before, at onset of and after VZV infection in 13 cases of VZV reactivation (localized zoster, •; disseminated zoster, ○). VZV infection within the first 6 months after HSCT (continuous line) and VZV infection at more than 6 months after HSCT (dashed line) are also indicated. (C) Correlation of preexisting anti-VZV titer and serum VZV DNA (localized zoster, •; disseminated zoster, ○). Preexisting anti-VZV titer and serum VZV DNA were inversely correlated (determined by Pearson correlation test; r = −0.90, P = 0.006).

Similar articles

Cited by

References

    1. Arvin, A. M. 2000. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 6:219-230. - PubMed
    1. Arvin, A. M. 2001. Varicella-zoster virus, p. 2731-2767. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, Pa.
    1. Centers for Disease Control and Prevention. 2004. CDC guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morbid. Mortal. Wkly. Rep. 49:RR-10. - PubMed
    1. Han, C. S., W. Miller, R. Haake, and D. Weisdorf. 1994. Varicella-zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 13:277-283. - PubMed
    1. Kalter, Z. G., S. Steinberg, and A. A. Gershon. 1997. Immune adherence hemagglutination: further observations on demonstration of antibody to varicella-zoster virus. J. Infect. Dis. 135:1010-1013. - PubMed

MeSH terms